Peter Hovstadius has a long career in both the pharmaceutical industry and academia. He has previously been in leading positions such as Chief Medical Officer at XNK Therapeutics, Chief Scientific Officer at Novartis and Research Director at MSD. Peter has through these roles, gained extensive experience in clinical drug development, and he has also been a driving force behind several important research and development initiatives in the pharmaceutical sector.

"I am very happy to become part of Lipum and working to improve treatment options for patients with chronic inflammatory diseases. It feels very inspiring to use my experience and expertise in a company that is so dedicated to making a difference for patients. I am really looking forward to working with the team at Lipum and contributing to our shared vision " says Peter Hovstadius.

Peter replaces Karin Franck-Larsson who has chosen to leave Lipum at her own request.

"I have had the privilege of working with Karin at both Lipum and Sobi. She has been a very appreciated colleague who has contributed greatly to Lipum with her expertise in rheumatology and drug development, and I would like to extend my genuine thank you to her. Peter has valuable and extensive experience in the role of CMO as well as pharmacology and clinical trials. His strong drive and commitment will contribute to the success of our continued clinical development. Peter will be an important member of our team, and I am pleased to welcome him to Lipum", says CEO Ola Sandborgh